There are no "issues" with using mortality as an endpoint. If there is, and you know that. Then surely they knew that when they structured the trial.

Is it harder? Yes. And that's why Leronlimab will take the lead. RLFTF changed the endpoint because they weren't confident they would get stat significance.

Cytodyn is betting they will. I like people who bet on themselves.